APX-3330
- Generic Name
- APX-3330
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
Phase 2
Completed
- Conditions
- Diabetic RetinopathyDiabetic Macular EdemaNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic Retinopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04692688
- Locations
- 🇺🇸
Clinical Site 11, Palm Desert, California, United States
🇺🇸Clinical Site 5, Beverly Hills, California, United States
🇺🇸Clinical Site 9, Phoenix, Arizona, United States
A Study of APX3330 in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Apexian Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03375086
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath